Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in ROS1+ NSCLC with Brain Metastases
NCT07083687Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07083687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083687.